Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis.

NCT00052052 is registered in ClinicalTrials.gov with InterMune as lead sponsor.

NCT NCT00052052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00052052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis.
Lead sponsor
InterMune
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2002
Completion date
September 30, 2004
Enrollment
210 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung disease, pulmonary fibrosis